Back to News
Market Impact: 0.32
FDA Approves ANI Pharma's Generic Everolimus Tablets
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
ANI Pharmaceuticals received final FDA approval for Everolimus Tablets for Oral Suspension, a generic version of Novartis' Afinitor Disperz. The drug is approved to treat certain conditions associated with tuberous sclerosis complex, expanding ANI's generic-product portfolio and creating a potential new revenue opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ANIP0.75
More News
- Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Oil industry warns a diesel export ban will raise fuel prices as Trump weighs restrictions
- Australia says OpenAI agent hacked Medicare portal